Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials.

@article{Urieto2004ExpressionAP,
  title={Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials.},
  author={Jeffrey O Urieto and Tiefu Liu and Jennifer H Black and Kimberley A. Cohen and Philip D. Hall and Mark C. Willingham and Lewis K Pennell and Donna Hogge and Robert J. Kreitman and Arthur Edward Frankel},
  journal={Protein expression and purification},
  year={2004},
  volume={33 1},
  pages={123-33}
}
A genetically engineered fusion toxin targeted to acute myeloid leukemia (AML) blasts was designed with the first 388 amino acid residues of diphtheria toxin with an H-M linker fused to human interleukin-3. The cDNA was subcloned in the pRK bacterial expression plasmid and used to transform BLR (DE3) Escherichia coli. A single transformed colony was grown in Superbroth with ampicillin; bacteria were centrifuged at an OD(650) of 1.3; master cell bank aliquots of bacteria in 30% glycerol… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

Similar Papers

Loading similar papers…